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ABSTRACT
Background Modulation and depletion strategies of 
regulatory T cells (Tregs) constitute valid approaches in 
antitumor immunotherapy but suffer from severe adverse 
effects due to their lack of selectivity for the tumor- 
infiltrating (ti- )Treg population, indicating the need for a 
ti- Treg specific biomarker.
Methods We employed single- cell RNA- sequencing 
in a mouse model of non- small cell lung carcinoma 
(NSCLC) to obtain a comprehensive overview of the 
tumor- infiltrating T- cell compartment, with a focus on 
ti- Treg subpopulations. These findings were validated by 
flow cytometric analysis of both mouse (LLC- OVA, MC38 
and B16- OVA) and human (NSCLC and melanoma) tumor 
samples. We generated two CCR8- specific nanobodies 
(Nbs) that recognize distinct epitopes on the CCR8 
extracellular domain. These Nbs were formulated as 
tetravalent Nb- Fc fusion proteins for optimal CCR8 binding 
and blocking, containing either an antibody- dependent 
cell- mediated cytotoxicity (ADCC)- deficient or an ADCC- 
prone Fc region. The therapeutic use of these Nb- Fc 
fusion proteins was evaluated, either as monotherapy or 
as combination therapy with anti- programmed cell death 
protein-1 (anti- PD-1), in both the LLC- OVA and MC38 
mouse models.
Results We were able to discern two ti- Treg populations, 
one of which is characterized by the unique expression 
of Ccr8 in conjunction with Treg activation markers. Ccr8 
is also expressed by dysfunctional CD4+ and CD8+ T 
cells, but the CCR8 protein was only prominent on the 
highly activated and strongly T- cell suppressive ti- Treg 
subpopulation of mouse and human tumors, with no 
major CCR8- positivity found on peripheral Tregs. CCR8 
expression resulted from TCR- mediated Treg triggering in 
an NF-κB- dependent fashion, but was not essential for 
the recruitment, activation nor suppressive capacity of 
these cells. While treatment of tumor- bearing mice with 
a blocking ADCC- deficient Nb- Fc did not influence tumor 
growth, ADCC- prone Nb- Fc elicited antitumor immunity 
and reduced tumor growth in synergy with anti- PD-1 
therapy. Importantly, ADCC- prone Nb- Fc specifically 
depleted ti- Tregs in a natural killer (NK) cell- dependent 
fashion without affecting peripheral Tregs.
Conclusions Collectively, our findings highlight the 
efficacy and safety of targeting CCR8 for the depletion of 
tumor- promoting ti- Tregs in combination with anti- PD-1 
therapy.
BACKGROUND
Regulatory T cells (Tregs) are an immuno-
suppressive subset of T lymphocytes known 
to play a crucial role in immune homeostasis 
and self- tolerance.1 They are characterized 
by the expression of the Foxp3 transcription 
factor, which is known to be a master regu-
lator of Treg differentiation and suppressor 
function.1 Several mechanisms have been 
reported through which Tregs can mediate 
their suppressive function, including the 
release of immunosuppressive cytokines 
such as interleukin (IL)-10 and TGF-β (trans-
forming growth factor- beta), the sequestering 
of IL-2 via the constitutive and high expres-
sion of CD25 and the cell- surface expression 
of immune checkpoint molecules such as 
CTLA-4, PD-1 and LAG-3.2
In the tumor microenvironment (TME), 
Tregs (tumor- infiltrating Tregs or ti- Tregs) 
have been shown to contribute to the suppres-
sion of antitumor immune responses and the 
development of an immunosuppressive TME 
in distinct cancer types.3 4 This protumoral 
role of Tregs is corroborated by the finding 
that a high Foxp3+ Treg infiltration correlates 
with a poor prognosis in multiple cancer 
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types.5 6 Moreover, Tregs have been shown to hamper the 
efficacy of immunotherapy,7 emphasizing the need for 
potent and specific ti- Treg targeting strategies.
Several Treg- modulating and Treg- depleting strategies 
have been shown to reduce tumor burden and increase 
the antitumor immune response in both experimental 
models and the clinic.8–16 However, despite their apparent 
therapeutic benefit, most of these strategies have severe 
drawbacks that need to be taken into consideration. Most 
importantly, the systemic depletion of Tregs can result in 
severe autoimmunity.5 Furthermore, current strategies 
mainly target molecules that are expressed on both Tregs 
and effector T cells, including CD259 12 17 and CTLA-4,8 10 
resulting in the potential ablation of tumor- reactive T 
cells. These findings highlight the need for a highly selec-
tive marker which allows the specific targeting of ti- Tregs, 
without affecting effector T cells and peripheral Tregs.
Several recent studies have determined the tran-
scriptome of ti- Tregs in distinct types of human cancer, 
including breast, hepatocellular, colorectal and non- 
small cell lung carcinoma (NSCLC) as well as (metastatic) 
melanoma,18–23 showing the consistent upregulation of 
the CCR8 gene.18–22 The CC chemokine receptor CCR8 
is a seven transmembrane G- protein coupled receptor 
(GPCR) with a high affinity for human/mouse CCL1, 
mouse CCL8 (mCCL8) and human CCL18 (hCCL18), 
the latter of which is a functional analog of mCCL8.24 
Interestingly, in patients with breast and pancreatic 
cancer, high CCR8+ Treg numbers correlated with more 
advanced stages of the disease and a decreased overall 
survival.20 25 However, multiple questions remain as to 
the nature of CCR8+ Tregs in the TME, the regulation of 
CCR8 expression and whether it is functionally involved 
in ti- Treg activity (providing the rationale for CCR8 
blockade) or should merely be considered as a biomarker 
for ti- Tregs (providing the rationale for CCR8 targeting 
and ti- Treg depletion).
To provide insight into these matters, we employed 
single- cell RNA- sequencing on the tumor T- cell infiltrate 
and identified two main ti- Treg subsets, one of which 
showing enhanced expression of CCR8 and various activa-
tion markers and displaying increased T- cell suppressive 
acitivity. CCR8 expression is the result of TCR- mediated 
Treg activation, but is not crucial for the recruitment, 
activation or suppressive capacity of these cells. Hence, 
selective natural killer (NK) cell- mediated depletion 
of the CCR8+ ti- Tregs using newly generated anti- CCR8 
nanobody- Fc fusions, caused a significant reduction in 
tumor growth and synergized with anti- PD-1 therapy, 
resulting in complete tumor remission and immunolog-
ical memory. However, CCR8 blockade alone without 




Female C57BL/6 mice were purchased from Janvier. 
Ccr8-/- (C57BL/6) and Foxp3Thy1.1 (C57BL/6) mice 
were kindly provided by Frank Tacke (Aachen Univer-
sity, Germany) and Adrian Liston (KULeuven, Belgium), 
respectively. OT- II (B6.Cg- Tg(TcraTcrb)425Cbn/J) mice 
were purchased from Charles River. Ccr8-/- and Foxp3Thy1.1 
mice were crossed to generate the Ccr8−/− Foxp3Thy1.1 
C57BL/6 mice.
Cell cultures and tumor models
The LLC- OVA, MC38 and B16- OVA cell lines were 
kindly provided by Dmitry Gabrilovich (The Wistar 
Institute, Philadelphia, USA), Massimiliano Mazzone 
(VIB- KULeuven, Belgium) and Karine Breckpot (Vrije 
Universiteit Brussel, Belgium), respectively. These cell 
lines and ex vivo culture of splenocytes and T cells were 
maintained as previously described.26 The LLC- OVA cells 
were harvested and resuspended to a concentration of 
3×106 cells/200 µl HBSS, which was subsequently injected 
into the right flank of syngeneic 6 to 12 week- old female 
C57BL/6 mice. Tumor volume was determined via caliper 
measurements and was calculated via the following 
formula: Volume = π × (d2 ×D)/6, where d symbolizes the 
minor tumor axis and D symbolizes the major tumor axis. 
In the case of anti- CCR8 Nb- Fc or anti- PD-1 monoclonal 
Ab (mAb) treatment, tumor- bearing mice were injected 
intraperitoneally with 200 µg of the respective nano-
body/Antibody or InVivoMab rat IgG2a isotype control 
Abs (clone 2A3) (Bio X Cell) in 100 µl of HBSS. A mouse 
IgG1- D265A Fc- silenced version of anti- mouse PD-1 mAb 
RMP1-14 was used that more closely reflects the mode 
of action of clinical anti- PD-1 mAbs (Absolute Antibody, 
catalog # Ab00813-1.32).27 28
In vivo cell depletion
NK cells were depleted during LLC- OVA tumor growth by 
intraperitoneal injection of 300 µg of anti- NK1.1 (PK136), 
2 days prior to the administration of isotype or anti- CCR8 
Nb- Fc (online supplemental figure S10A). Neutrophils 
were depleted by alternating (24 hours) intraperitoneal 
injections of 75 µg of anti- Ly6G (1A8) and 150 µg of 
mouse anti- rat (MAR18.5),29 4 days prior to the adminis-
tration of anti- CCR8 Nb- Fc (online supplemental figure 
S10A). Macrophages were depleted by feeding the mice 
chow containing the highly selective CSF- 1R inhibitor 
PLX5622, starting 5 days prior to the administration of 
anti- CCR8 Nb- Fc (online supplemental figure S10A). The 
other treatment groups received control chow.
In silico analysis of TCGA data
Human data was recovered from The Cancer Genome 
Atlas (TCGA) (available at http:// cancergenome. nih. 
gov) and analyzed using R2 (available at http:// r2. amc. 
nl), a genomics analysis and visualization platform, and 
GraphPad Prism 8.0 software.
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Lung cancer and melanoma patient samples
Blood samples and fresh tumor tissue were obtained 
from 11 healthy donors and from 11 patients, respec-
tively, undergoing surgical resection at three Belgian 
hospitals: UZ Brussel (melanoma samples) and CUSL 
and CHU UCL Namur (NSCLC samples and healthy 
donors). Clinical patient information can be found in 
online supplemental table S2. After resection, samples 
were immediately transported on ice to the research 
facilities at the Vrije Universiteit Brussel. Human 
tumor single cell suspensions were prepared as previ-
ously described.26
Ex vivo single-cell preparation, flow cytometry, cell sorting
Preparation of single cell suspensions, subsequent flow 
cytometric analysis and/or cell sorting is described 
in detail in the online supplemental materials and 
methods.
Single cell RNA sequencing using the 10x Genomics platform
Single- cell suspensions derived from the tumor were 
obtained using the above- mentioned procedures. For 
the analysis of the T- cell infiltrate, we pooled five tumors 
grown for 12 days in wild type (WT) C57BL/6 mice. The 
single cell suspensions were stained with APC- Cy7- labeled 
anti- CD45, PeCy7- labeled anti- CD11b, FITC- labeled anti- 
TCRβ and DAPI. Subsequently, approximately 50,000 live 
CD45+CD11b−TCRβ+ cells were sorted into ME medium 
using the BD FACSAria III (BD Biosciences). The sorted 
cells were subsequently centrifuged and resuspended in 
PBS (phosphate buffered saline) +0.04% bovine serum 
albumin at room temperature at an estimated final concen-
tration of 1000 cells/µl. Next, the single- cell Bead- in 
Emulsions and single- cell RNA- sequencing (scRNA- seq) 
library was prepared as previously described.30 The 
scRNA- seq experiment was performed once, giving rise to 
a scRNA- seq libraries encompassing approximately 2730 
single cells. The obtained sequencing library was then 
sequenced as previously described,30 the average of the 
mean reads per cell across was >32,000, with an average 
sequencing saturation metric of >68%. The gene expres-
sion matrices were preprocessed and filtered using the 
SCRAN and Scater R packages.31 The detection of outlier 
cells, generation of PCA plots, removal of low- abundance 
genes, normalization and unsupervised clustering were 
performed as previously described.30 The obtained clus-
tering was visualized in two- dimensional scatter plots 
via Uniform Manifold Approximation and Projection 
(UMAP) using the Seurat V3.0 R package.
Single-cell regulatory network inference and clustering using 
pySCENIC
We performed pySCENIC by starting from the filtered 
raw counts and following the proposed workflow using 
the latest Singularity image. The pySCENIC output 
(loom file) was then analyzed using the SCopeLoomR 
R package. We created a binary heatmap indicating if a 
regulon is active or not in a particular cell, based on the 
output area under the recovery curve (AUC) values and 
AUC thresholds. Besides plotting the binary values, we 
also transformed these AUC values into values ranging 
from 0 to 1 for each regulon and plotted this in a heatmap 
with a blue–red color scale. The aheatmap function of the 
NMF R package was used for creating the heatmap and 
the regulons are clustered hierarchically.
RNA extraction and cDNA preparation for qPCR
RNA extraction and subsequent qPCR reaction were 
performed as previously described,26 a detailed descrip-
tion of the procedures can be found in the online supple-
mental materials and methods.
Suppression assays and OT-II T cell activation
The suppression assays and OT- II T cell activation were 
performed as previously described,26 a detailed descrip-
tion of the procedures can be found in the online supple-
mental materials and methods.
Adoptive Treg transfer
Splenic (CD4+CD25+) Tregs were isolated from both WT 
C57BL/6 and OT- II spleens as described in the online 
supplemental materials and methods. The obtained 
Tregs were labeled with CellTrace Violet (Thermo 
Fisher Scientific) and subsequently resuspended in 
HBSS to a final concentration of 6×105 cells/20 µl. Of 
this single cell suspension, 20 µl was injected directly 
into the tumor of day 9 LLC or LLC- OVA subcutane-
ously tumor- bearing mice. After 48 hours, the tumors 
from each group were collected and processed to a 
single cell suspension. Using flow cytometry, the Cell-
Trace+ cells within the TME were evaluated for their 
upregulation of CCR8 expression.
Immunizations and phage display selections
Nanobodies were generated through immunization of 
llamas and alpacas with DNA as previously described.32 33 
A brief description of the procedures can be found in the 
online supplemental materials and methods.
Screening of CCR8 selection outputs
Nb clones from the mouse CCR8 immunization and selec-
tion campaign, were screened by means of flow cytometry 
for binding to HEK293 cells that were transiently trans-
fected with full length mouse CCR8 or with N- terminal 
deletion mouse CCR8 (delta16- 3XHA) plasmid DNA 
(online supplemental table S1), in comparison to mock 
transfected control cells. A detailed description of the 
procedures can be found in the online supplemental 
materials and methods.
Cloning, expression and purification of Nb-Fc fusions
Tetravalent Nb- Fc constructs were generated combining a 
copy each of Nb- I and Nb- II per Fc arm separated by a 10 
amino acid flexible GlySer linker and fused by a second 
10 amino acid flexible GlySer linker to the hinge region 
of the mouse IgG2a Fc domain. A detailed description of 
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the generation of these constructs can be found in the 
online supplemental materials and methods.
Binding and competition experiments, cAMP HTRF assay for 
Gi-coupled receptors and apoptosis assay
A detailed description of the procedures used to char-
acterize the nanobody constructs can be found in the 
online supplemental materials and methods.
Histology
A detailed description of the procedures used for histo-
logical analysis of colon and ileum tissues can be found in 
the online supplemental materials and methods.
FITC–dextran intestinal permeability assay
A detailed description of the procedures used to charac-
terize intestinal permeability can be found in the online 
supplemental materials and methods.
Statistics
All graphs show mean±SEM. Statistical significance (p 
value <0.05) was determined in GraphPad Prism 8.0 soft-
ware. For relevant pairwise comparisons, either paired 
or unpaired Student’s t- tests were performed. For the 
comparison of multiple groups, one- way analysis of vari-
ance (ANOVA) was performed, followed by a post- test. 
Tumor growth curves were compared by two- way ANOVA 
with Holm- Sidak multiple comparisons test. To assess 
correlation, a Pearson correlation coefficient was calcu-
lated. For statistically significant differences, the p value 
is indicated in graphs as the following: *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.
RESULTS
Expression of Ccr8 is detected in three distinct tumor-
infiltrating T-cell subpopulations
To obtain an idea about the expression pattern of Ccr8 
in the TME, Ccr8 expression was first assessed via qRT- 
PCR within the CD45+ hematopoietic and CD45− non- 
hematopoietic fraction of subcutaneously grown Lewis 
Lung Carcinoma (LLC)- OVA, B16- OVA melanoma and 
MC38 colon carcinoma tumors. Ccr8 expression was 
restricted to the CD45+ hematopoietic cells (figure 1A, 
online supplemental figure S1A), and more specifically to 
the CD11b−TCRβ+ T/NKT- cell compartment (figure 1B). 
To further identify the Ccr8- expressing cells within the 
CD45+CD11b−TCRβ+ compartment of LLC- OVA tumors, 
we relied on single- cell RNA- sequencing using the 10x 
chromium platform (figure 1C). Unsupervised clus-
tering, dimensionality reduction and UMAP projections 
were performed on 2.603 tumor- infiltrating T/NKT cells 
(figure 1D) and individual clusters were identified based 
on their expression of known marker genes (figure 1E). 
Among the CD8+ T cells, the CD8_S1 cluster showed 
high expression levels of Bcl2, Sell (CD62L), Tcf7 and Lef1 
(figure 1E, online supplemental figure S1B), indicative of 
a memory CD8+ T cell phenotype.34–36 The CD8_S2 cluster 
represented the largest fraction of tumor- infiltrating 
CD8+ T cells (figure 1D) and was marked by the expres-
sion of several genes associated with effector CD8+ T 
cells (Gzmk, Gzma, Gzmb, Klrc1, Klrd1, Ccr5 and Ccr2)37 
(figure 1E, online supplemental figure S1B). Finally, the 
CD8_S3 cluster also showed a highly activated CD8+ T 
cell phenotype, but with the additional elevated expres-
sion of Ifng, Tnfrsf4 (OX-40, CD134), Tnfrsf9 (4- 1BB, 
CD137) and several immune checkpoint molecules such 
as Pdcd1 (PD-1), Lag3 (CD223), Havcr2 (TIM-3) and 
Cd160, indicative of a dysfunctional CD8+ T- cell pheno-
type (figure 1E,F, online supplemental figure S1B)38 . 
Interestingly, Ccr8 expression could be detected in a frac-
tion of these dysfunctional CD8+ T cells (figure 1G). Ccr8 
was also expressed in the CD4_S2 cluster, which showed 
high expression levels of Pdcd1, Lag3 and Tnfrsf4, but also 
of the activation markers Cd70 and Cd83 (figure 1E–G), 
suggesting that these are dysfunctional CD4+ T cells. 
Other CD4+ T cell clusters included the naive CD4_S1 
cluster (high expression of Cd4 and Cxcr3), the CD4_Th17 
cluster (high expression of Il17re, Ccr6, Rorc and Rora) 
and cluster CD4_S3 (increased expression of Il7r, Socs3, 
Asap1 and Tcf7) (figure 1E, online supplemental figure 
S1B), all of which were Ccr8- negative. Conversely, CD4+ 
regulatory T cells (CD4_Treg), identified based on their 
high expression of Treg- associated genes such as Foxp3 
(figure 1E,H and online supplemental figure S1B), Klrg1, 
Ctla4 (figure 1H), Tnfrsf4, Tnfrsf9, Tnfrsf18 (GITR), Cd81, 
Il2ra (CD25), Icos (CD278) and Il10 (figure 1E,H), were 
partly Ccr8- positive, indicating that there might be distinct 
Treg subsets present within the TME (figure 1G). Finally, 
Ccr8 expression was negative in cluster T_IFN (increased 
expression levels of multiple interferon- induced genes 
such as Rsad2, Ifit3 (figure 1E), Ifit3, Ifit1 and Isg15 (online 
supplemental figure S1B)), cluster PrCs (high expression 
of cell cycle genes, including Mki67, Top2a, Hmmr, Ezh2, 
Cenpa and Mcm5 (figure 1E, and online supplemental 
figure S1B)) and cluster NKT (expression of NK- associ-
ated genes such as Klrb1c (NK1.1, figure 1E), Klra7, Klra6 
and Klre1 (online supplemental figure S1B)).
Overall, these data show that the expression of Ccr8 
within the LLC- OVA tumor immune compartment is 
restricted to a subset of Tregs, but also to populations of 
dysfunctional CD8+ and CD4+ T cells.
scRNA-seq analysis reveals the presence of two main tumor-
infiltrating Treg populations, one of which expresses Ccr8
To obtain a more detailed insight in the heterogeneity 
of the Treg compartment, 289 cells belonging to the 
CD4_Treg cluster were re- clustered, revealing two distinct 
Treg subsets (Treg_S1 and Treg_S2, figure 2A,B). Both 
clusters showed expression of Foxp3, though this Treg 
master regulator gene was significantly higher expressed 
in Treg_S1 (figure 2C). Moreover, the Treg_S1 subset 
showed higher expression levels of several activation 
markers and immune checkpoint molecules, including 
Lag3, Klrg1, Tnfrsf4, Tnfrsf9 and Il2ra, but also of tran-
scription factor Ikzf2 (Helios), co- stimulatory molecule 
Cd81 and secretory molecules Areg and Il10 (figure 2B,C), 
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indicative of a highly suppressive phenotype. Aside from 
these well- defined Treg markers, Treg_S1 also showed 
significantly higher expression of Itgb8, Bmyc, Cst7, Wls 
and Sdf4 (figure 2B,C). Finally, Ccr8 was mainly expressed 
in this highly activated Treg_S1 subset (figure 2B,C).
Conversely, the Treg_S2 subset was characterized by a 
significantly higher expression of Saraf, Emb, Serpinb1a, 
Ifit1bl1, Gbp2b and the GITR- associated membrane adap-
tors Ms4a6b and Ms4a4b.39 Interestingly, Treg_S2 also 
showed significantly higher expression levels of the tran-
scription factor Rorc and chemokine receptors Ccr4 and 
Figure 1 Single cell RNA- seq analysis of the LLC- OVA tumor- infiltrating T- cell compartment. (A) Ccr8 expression in the CD45+ 
hematopoietic cell subset and CD45− non- hematopoietic cell subset of LLC- OVA tumors measured via qRT- PCR (n=4). (B) Ccr8 
expression in the CD45+CD11b+, CD45+CD11b−TCRβ+ and CD45−CD11b−TCRβ− cell subsets measured via qRT- PCR (n=3). (C) 
Schematic overview of the single cell RNA- seq experiment. (D) UMAP plot of 2.603 WT NKT/T cells isolated from s.c. LLC- OVA 
tumors revealing the presence of 11 T- cell subsets. (E) Dot plot showing the relative gene expression of several signature genes 
within the distinct T- cell subsets. The size of the dots relates to the % positive cells within each T- cell population. The color 
code relates to the relative expression level of the gene. (F) UMAP plots showing expression of several key marker genes of 
the CD8_S3 subset. (G) UMAP plots showing expression of several key marker genes of the CD4_S2 subset. (H) UMAP plots 
showing expression of several key marker genes of the CD4_Treg subset. (A, B) Data shown as mean±SEM. (A) ***p<0.001 by 
paired Student’s t- test, (B) *p<0.05 by one- way ANOVA. ANOVA, analysis of variance; LLC, Lewis Lung Carcinoma; mRNA, 
messenger RNA; NK, natural killer; s.c., subcutaneously; Treg, regulatory T cell; UMAP, Uniform Manifold Approximation and 
Projection; WT, wild type.
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Ccr6 (figure 2B,C), together suggesting a more Th17- 
like Treg phenotype, as has been previously described.40 
Other well- known T- cell activation genes such as Cd44 
and Ctla4 showed similar expression levels in both Treg 
subsets (figure 2C).
The CCR8 protein is predominantly upregulated by the highly 
activated and strongly suppressive Treg subpopulation in both 
mouse and human tumors
We next evaluated the expression pattern of the CCR8 
protein within tumor single cell suspensions via multi-
color flow cytometry. No CCR8 could be detected at 
the surface of non- hematopoietic (CD45−) and myeloid 
(CD45+CD11b+) cell populations (gating strategy, 
online supplemental figure S2A). Within the lymphoid 
(CD45+CD11b−) subsets, CCR8 expression was observed 
on approximately 25% of the CD4+Foxp3−LAG-3High 
cells (cluster CD4_S2) and CD4+Foxp3+LAG-3Low Tregs 
(Treg_S2), and on approximately 60% of the CD4+Fox-
p3+LAG-3High Tregs (Treg_S1) (figure 3A), but not on CD4- 
negative T cells (figure 3A, online supplemental figure 
S2A). These data largely corroborate the gene expression 
data, except for the CD8+LAG-3High cells (CD8_S3), for 
which the observed presence of Ccr8 messenger RNA does 
not translate at the protein level. Within the CCR8+ T cell 
fractions, CCR8 density (as measured by median fluores-
cence intensity (MFI)) appeared highest on the CD4+Fox-
p3+LAG-3High Tregs (Treg_S1) (figure 3B). This CCR8 
expression by ti- Tregs is not unique for the LLC- OVA 
model, with approximately 43% and 65% of all ti- Tregs 
Figure 2 Single cell RNA- seq analysis of the ti- Tregs. (A) UMAP plot of 289 ti- Tregs isolated from s.c. LLC- OVA tumors 
revealing the existence of two ti- Treg subsets. (B) Volcano plot showing the genes that are differentially expressed between 
Treg_S1 and Treg_S2. (C) Violin plots showing expression of several key marker genes of the Tregs_S1 (red) and Treg_S2 
(turquoise) subsets. (C) *p<0.05, **p<0.01 and ****p<0.0001 by unpaired Student’s t- test. LLC, Lewis Lung Carcinoma; s.c., 
subcutaneously; ti- Treg, tumor- infiltrating regulatory T cell; UMAP, Uniform Manifold Approximation and Projection.
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Figure 3 CCR8 is mainly expressed on the highly activated ti- Tregs. (A) Percentage CCR8+cells within different LLC- OVA 
tumor- infiltrating lymphoid cell subsets as measured via flow cytometry (n=5). (B) CCR8 expression level (MFI) on the CCR8+ 
tumor- infiltrating T- cell populations as measured via flow cytometry (n=4). (C) Percentage CCR8+cells within Tregs in different 
organs of tumor- bearing (dark blue) and naive C57BL/6 mice (light blue) as measured via flow cytometry (n=5). (D) Expression 
(ΔMFI) of LAG-3, OX-40, Helios, KLRG1, CD25, CD44, CD69 and GARP in the CD4+Foxp3- (black circle), CD4+Foxp3+CCR8+ 
(red square) and CD4+Foxp3+CCR8- (turquoise triangle) T- cell subsets as determined via flow cytometry (n=6). (E) Treg 
suppression assay. Splenic CD8+ T- cell proliferation after stimulation (anti- CD3+anti- CD28) in the presence of CCR8+ (red) 
or CCR8− (turquoise) ti- Tregs at a ratio of one ti- Treg for five splenic T cells (1:5). (F) Representative flow cytometry plots 
showing Isotype/CCR8 expression (MFI) by non- Tregs and ti- Tregs of NSCLC patients. (G) Percentage CCR8+cells within 
different lymphoid subsets found in the blood or tumors of patients with NSCLC or healthy volunteers as measured via flow 
cytometry (n=9-11). (H) Percentage OX-40+cells within different lymphoid subsets found in the tumors of patients with NSCLC 
as measured via flow cytometry (n=9). (I) Expression of the CCR8 gene within cancerous and surrounding healthy tissue of 
bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colorectal cancer (CRC), head and neck squamous cell 
carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma 
(KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate 
adenocarcinoma (PRAD), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma 
(UCEC) and skin cutaneous melanoma (SKCM) (data retrieved from TCGA). (J) Correlation between the expression of FOXP3 
and CCR8 in different human tumors (data retrieved from TCGA). (A to D and G to I) Data shown as mean±SEM. (B, D, G, H) 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 by one- way ANOVA, (C, I) *p<0.05, **p<0.01 and ****p<0.0001 by (un)paired 
Student’s t- test. ANOVA, analysis of variance; LLC, Lewis Lung Carcinoma; NK, natural killer; NSCLC, non- small cell lung 
carcinoma; TCGA, The Cancer Genome Atlas; ti- Treg, tumor- infiltrating regulatory T cell.
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staining positive for CCR8 in the MC38 and B16- OVA 
models, respectively (online supplemental figure S2B).
We next assessed CCR8 expression on Foxp3+ Tregs 
from distinct organs in LLC- OVA- bearing and naive mice 
(figure 3C). In naive animals, CCR8 was hardly detect-
able on Tregs from all tissues except the thymus, where 
approximately 8% of Tregs were CCR8+, illustrating that 
this is part of a normal physiological process in that organ 
(figure 3C). In tumor- bearing animals, CCR8+ Tregs 
were also observed in the thymus, but in addition also in 
the spleen (approximately 9% of the Tregs) and tumor- 
draining lymph node (approximately 12% of the Tregs) 
(figure 3C). However, this expression level was by far not 
as high as on Tregs in the TME, where CCR8 was found 
on approximately 57% of all Tregs (figure 3C). These data 
suggest a gradual increase in the percentage of CCR8+ 
Tregs from peripheral organs, to lymphoid organs, to 
the tumor site. Interestingly, also the density of CCR8 
surface expression (as measured by MFI) on CCR8+ Tregs 
gradually increased from thymus, to spleen and further 
to tumor- draining lymph node and TME (online supple-
mental figure S2C).
We then assessed whether CCR8 is part of a larger 
Treg activation program, as suggested by the scRNA- seq 
data. CCR8+ ti- Tregs indeed showed a significantly higher 
surface expression level of Treg activation markers such 
as LAG-3, OX-40, Helios, KLRG1, CD25, CD44, CD69 
and GARP in LLC- OVA (figure 3D), MC38 and B16- OVA 
tumors (online supplemental figure S2D). This correlated 
with a higher T- cell suppressive capacity of CCR8+ ti- Tregs 
compared with CCR8- ti- Tregs, illustrated by a significant 
reduction of polyclonal CD8+ and CD4+ T- cell prolifera-
tion (figure 3E; online supplemental figure S2E). Collec-
tively, these results indicate that CCR8 is predominantly 
expressed on highly activated and suppressive ti- Tregs.
We next assessed CCR8 expression on tumor- infiltrating 
T cells from freshly resected human NSCLC and mela-
noma tumor samples. CCR8 expression could be detected 
on approximately 40% of the CD3+CD4+CD127−CD25+ 
Tregs within NSCLC tumors (figure 3F,G). Interestingly, 
these CCR8+ ti- Tregs also showed significantly higher 
expression levels of OX-40, suggesting an overall higher 
activation state (figure 3H). Similar to the mouse model, 
a much smaller subset of CD4+CD127+CD25− non- Treg 
cells were CCR8- positive, while CD8+ T cells were nega-
tive for CCR8 in these tumors (figure 3F,G). Notably, all 
these T- cell populations, including the Tregs, were mostly 
negative for CCR8 in the peripheral blood (figure 3G). 
Similar observations were made in patients with mela-
noma (online supplemental figure S2F), corroborating 
the notion that CCR8 expression can be used as a marker 
of ti- Tregs in distinct human cancer types. To further 
broaden this notion, we mined the TCGA platform to 
compare CCR8 expression levels in distinct human tumors 
with their surrounding healthy tissue. CCR8 expression was 
significantly upregulated in the TME of multiple tumor 
types (figure 3I), always showing a significant (p<0,0001) 
correlation with FOXP3 expression (figure 3J). These data 
indicate FOXP3+ ti- Tregs as important CCR8 expressors in 
human tumors.
CCR8 is upregulated in response to TCR stimulation
We next aimed to understand the mechanism of CCR8 
upregulation. First, we applied the SCENIC pipeline on 
the LLC- OVA tumor- infiltrating T/NKT cells to identify 
the master regulators that drive Ccr8 expression in the 
distinct T- cell subsets.41 This allowed us to identify key 
regulons within each T- cell population, after which the 
cells were re- clustered based on their regulon activity and 
were colored by their matching Seurat clusters (online 
supplemental figure S3A). Within the CD4_Treg popu-
lation, SCENIC identified several master regulators of 
the Treg phenotype, including Foxp3, Cebpb, Prdm1, Bcl3 
and Nfkb2 (figure 4A, online supplemental figure S4). 
Of these, Nfkb2 was predicted to be a Ccr8 regulator and 
was shown to be active in the three Ccr8 expressing T- cell 
clusters: CD4_Treg, CD8_S3 and CD4_S2 (figure 4A, 
online supplemental figure S4). Interestingly, NF-κB is 
strongly involved in TCR signaling, suggesting that T- cell 
activation could be a trigger for Ccr8 expression. Anal-
ysis of genome- wide chromatin immunoprecipitation 
(ChIPseq) data of the NF-κB p65 subunit as published 
by Oh et al42 showed several p65 binding peaks associated 
with the Ccr8 gene upon Treg stimulation (figure 4B). 
To validate these findings, we polyclonally stimulated 
total splenocytes, resulting in up to 40% of splenic Tregs 
becoming CCR8+ (figure 4C). Also CD4+Foxp3− T cells 
turned CCR8+, although to a much lesser extent, whereas 
the CD8+ T cells showed no CCR8 upregulation (online 
supplemental figure S3B). To assess whether an antigen- 
specific T- cell activation yields the same effect, OT- II 
or control C57BL/6 splenocytes were cultured in the 
presence of ovalbumin. Only splenic OT- II Tregs signifi-
cantly upregulated CCR8, demonstrating that antigen 
responsiveness is a determinant for CCR8 expression 
(figure 4C). The same results were obtained with Tregs 
derived from the lymph node (figure 4D, online supple-
mental figure S3C). Interestingly, splenocyte stimulation 
in the presence of the NF-κB inhibitor CAPE resulted 
in a dose- dependent reduction of CCR8 upregulation 
on the Tregs (figure 4E), whereas Treg viability was only 
slightly affected at the highest concentration (online 
supplemental figure S3D), highlighting the importance 
of NF-κB signaling for CCR8 regulation.
To verify whether antigen recognition also results in 
CCR8 upregulation in vivo, we adoptively transferred 
CellTrace- labeled OT- II splenic Tregs into the tumor of 
LLC- OVA- bearing mice, resulting in the upregulation of 
CCR8 expression on a fraction of these cells (figure 4F). 
No CCR8 upregulation was observed when the same 
OT- II Tregs were transferred into the tumors of LLC- 
bearing mice, indicating that a lack of antigen recognition 
prevents subsequent CCR8 induction. Together, these 
results demonstrate that CCR8 upregulation on ti- Tregs 
is induced in an NF-κB dependent manner and initiated 
by TCR stimulation through tumor antigen recognition.
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CCR8 is redundant for the recruitment, activation or 
suppressive capacity of ti-Tregs
To evaluate the potential roles of CCR8 on ti- Tregs, we 
first assessed whether CCR8 mediates Treg homing to the 
TME. The overall presence of ti- Tregs (figure 5A), as well 
as the percentage of activated CD4+Foxp3+OX-40+ ti- Tregs 
(Treg_S1), 70% of which are CCR8+, was unchanged 
within the CD45+ population of LLC- OVA tumors grown 
in CCR8- KO or WT littermate control mice (figure 5B). 
Also, the presence of CD4+Foxp3-LAG-3High cells (CD4_
S2), a fraction of which expresses CCR8 (figure 3A), was 
unaltered (figure 5C). These data argue against a domi-
nant role for CCR8 in recruiting CCR8+ T cells towards the 
TME. Moreover, in LLC- OVA tumors, no significant differ-
ences in activation marker expression (figure 5D) nor 
T- cell suppressive capacity (figure 5E) could be observed 
between WT and CCR8- KO ti- Tregs, indicating that CCR8 
is not majorly involved in Treg activation within the TME.
Figure 4 CCR8 upregulation is induced by TCR stimulation. (A) UMAP plots showing the activity of the Foxp3, Cebpb, Prdm1, 
Bcl3 and Nfkb2 regulons within the distinct T- cell subsets, cells in which the regulons are active are indicated in blue. (B) ChIP- 
seq (p65) signal profiles across the Ccr8 locus. Data obtained from Oh et al.42 Peaks that are gained after Treg stimulation are 
highlighted (gray). (C) Percentage CCR8+ cells within C57BL/6 or OT- II splenic Tregs after 24 hours of in vitro co- culture with 
TCR stimulants (anti- CD3 +anti- CD28) or Chicken ovalbumin (OVA) (n=3). (D) Percentage CCR8+ cells within C57BL/6 or OT- II 
LN- derived Tregs after 24 hours of in vitro co- culture with TCR stimulants (anti- CD3+anti- CD28) or Chicken ovalbumin (OVA) 
(n=3). (E) Percentage CCR8+ cells within C57BL/6 splenic Tregs after 24 hours of in vitro co- culture with TCR stimulants (anti- 
CD3+anti- CD28) and distinct concentrations of CAPE (n=4). (F) Percentage CCR8+ cells within transferred C57BL/6 or OT- II 
splenic Tregs 48 hours after intratumoral (i.t.) adoptive transfer into LLC or LLC- OVA tumors (n=3). (C to F) Data shown as 
mean±SEM. (C, D) ***p<0.001 and ****p<0.0001 by one- way ANOVA where each condition was compared with prior to culture, 
(E, F) *p<0.05 and **p<0.01 by one- way ANOVA. ANOVA, analysis of variance; LLC, Lewis Lung Carcinoma; UMAP, Uniform 
Manifold Approximation and Projection.
G
eneeskunde - P




















10 Van Damme H, et al. J Immunother Cancer 2021;9:e001749. doi:10.1136/jitc-2020-001749
Open access 
This lack of ti- Treg phenotype in CCR8- KO mice 
translated into an indistinguishable LLC- OVA tumor 
growth curve between CCR8- KO mice and WT littermate 
control mice (figure 5F), reflected by a similar immune 
composition of LLC- OVA tumors in both backgrounds 
(figure 5G,H, online supplemental figure S5, gating 
strategy online supplemental figure S6). Collectively, 
these results demonstrate that CCR8 is redundant for 
the recruitment, activation and suppressive capacity of 
ti- Tregs.
Generation of tetravalent nanobody-Fc fusions that allow the 
specific blockade of CCR8 signaling
We next assessed CCR8 as a molecular target in ther-
apeutic approaches that aim to mitigate the immuno-
suppressive ti- Treg population, without affecting Tregs 
in other tissues. Hereto, we generated anti- CCR8 nano-
bodies (Nbs, camelid single domain antibody fragments) 
through repeated immunization of llamas and alpacas 
with mouse CCR8- encoding plasmid DNA, as outlined 
in the online supplemental materials and methods. 
Figure 5 CCR8 is redundant for the functionality of ti- Tregs. (A) Percentage of Foxp3+ Tregs within the CD45+ population of 
LLC- OVA tumors in CCR8- KO (blue) and WT littermate (black) control mice (n=5–6). (B) Percentage of OX-40+ Tregs and OX-40− 
Tregs that stains positive for CCR8 expression (n=5-6) (and) Percentage of OX-40+ Tregs within the CD45+ population of D14 
LLC- OVA tumors in WT littermate (black) and CCR8- KO (blue) mice (n=7). (C) Percentage of CD4+Foxp3−LAG-3high cells within 
the CD45+ population of LLC- OVA tumors in CCR8- KO (blue) and WT littermate (black) control mice (n=7). (D) Comparison of 
activation marker expression between ti- Tregs of the WT (black) and CCR8- KO (blue) TME in LLC- OVA tumors (n=7). (E) Treg 
suppression assay. Splenic CD8+ T- cell proliferation after stimulation (anti- CD3 + anti- CD28) in the presence of WT (black) or 
CCR8- KO (blue) ti- Tregs at distinct ti- Treg:splenic T cell ratios. (F) Tumor growth of s.c. injected LLC- OVA in CCR8- KO (blue) 
and WT littermate (black) control mice (n=7). (G) Influx of CD45+ cells within the TME of D13 LLC- OVA tumors grown in CCR8- 
KO (blue) or WT littermate (black) control mice (n=5-6). (H) Influx of distinct myeloid cell types (% of CD45+ cells) and lymphoid 
cell types (% of CD45+ cells) within the TME of D13 LLC- OVA tumors grown in CCR8- KO (blue) versus WT littermate (black) 
control mice (n=5–6). (A to H) Data shown as mean±SEM. (A to E, G, H) ****p<0.0001 by unpaired Student’s t- test, (F) by two- 
way ANOVA with Holm- Sidak multiple comparisons test. ANOVA, analysis of variance; LLC, Lewis LungCarcinoma; NK, natural 
killer; s.c., subcutaneously; TME, tumor microenvironment; ti- Treg, tumor- infiltrating regulatory T cell; WT, wild type.
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Phage display libraries derived from peripheral blood 
mononuclear cells were prepared and subjected to two 
consecutive selection rounds on HEK293T and CHO- K1 
cells transiently transfected with mouse CCR8. Selected 
Nbs were then screened for binding to HEK293T cells 
transfected with either full length or N- terminally deleted 
mouse CCR8 (online supplemental table S1), in compar-
ison to mock transfected cells, allowing their classification 
as N- terminal mouse CCR8 binders (only binding to full 
length CCR8) or extracellular loop mouse CCR8 binders 
(binding on full length and N- terminally deleted CCR8). 
Ultimately, two Nbs were chosen, with Nb- I requiring the 
presence of the N- terminus for binding, and Nb- II not 
(online supplemental figure S7A).
Nb- I and Nb- II were then combined into a tetravalent 
Nb- Fc fusion by covalent linking of Nbs with flexible 
peptide linkers (Nb- Fc1, figure 6A). Similar multivalent 
constructs are known to improve potency and efficacy 
through intermolecular and intramolecular avid binding 
on their respective chemokine receptor targets.43–47 
Whereas Nb- Fc1 carries the wild type mouse IgG2a Fc 
moiety, Nb- Fc1A carries a LALAPG full- effector knockout 
version (no complement binding, fixation and antibody- 
dependent cell- mediated cytotoxicity (ADCC))48 and 
Nb- Fc1B carries an afucosylated Fc for enhanced ADCC 
function.49 The Nb- Fc fusions potently bind to mouse 
CCR8, with Nb- Fc1, Nb- Fc1A and Nb- Fc1B displaying 
comparable EC50 values in the nanomolar range of 
binding to endogenously expressed CCR8 on mouse 
BW5147 thymoma cells (online supplemental figure 
S7B). Next, dilution series of monovalent Nb- I and/or 
Nb- II were competed against Nb- Fc1 on BW5147 cells. An 
equimolar mixture of Nb- I and Nb- II appeared more effi-
cient in displacing the binding of Nb- Fc1, compared with 
each of the nanobodies individually (online supplemental 
figure S7C), revealing that both nanobodies contribute 
to the avid binding of the Nb- Fc fusions. To assess their 
CCR8 blocking capacity, CCR8 expressing CHO- K1 
cells were treated with the CCR8- ligand CCL1 and its 
inhibitory effect on cAMP accumulation was measured 
via homogenous time- resolved fluorescence detection 
(HTRF) in the presence or absence of Nb- Fc fusions. 
Nb- Fc1 potently blocked the action of CCL1 (online 
supplemental figure S7D). Similarly, the different Nb- Fc 
moieties, potently inhibited the protective effect of CCL1 
against dexamethasone- induced apoptosis of BW5147 
cells (online supplemental figure S7E). Together, these 
data support the notion that the Nb- Fc fusions potently 
inhibit the function of mouse CCR8 through the concom-
itant binding of Nb- I and Nb- II to distinct epitopes.
Specific depletion of CCR8+ ti-Tregs, but not CCR8 
blockade, results in reduced tumor growth and increased 
responsiveness to immune checkpoint blockade therapy
LLC- OVA tumor- bearing mice were treated with Nb- Fc1A, 
which blocks CCR8 but cannot perform any Fc- mediated 
function (termed Anti- CCR8 (block) in the Figures), 
and with Nb- Fc1B, which also blocks CCR8 but mediates 
ADCC (termed Anti- CCR8 (ADCC)). Intraperitoneal 
administration of 200 µg of Nb- Fc1A was done at days 4 
and 11 of LLC- OVA tumor growth, resulting in an effi-
cient occupation of CCR8 inside the TME (figure 6B), 
but also in the spleen (online supplemental figure S8A), 
as illustrated by the prevention of subsequent anti- CCR8 
mAb binding. Nevertheless, no change in tumor growth 
was observed (figure 6C), along with an unaltered infil-
tration of CD45+ hematopoietic cells (figure 6D), various 
lymphoid cell populations (online supplemental figure 
S8B) and ti- Tregs in these tumors (figure 6E, gating 
strategy online supplemental figure S6). Moreover, the 
ti- Tregs expressed similar levels of activation markers 
(figure 6F). Notably, CCR8 blockade alone also did not 
affect the subcutaneous growth of MC38 colon carcinoma, 
a hot tumor that is known to be responsive to immuno-
therapy (online supplemental figure S8C). Overall, and 
in accordance with the observations in CCR8- KO mice, 
CCR8 blockade by itself appears not to be sufficient to 
affect tumor growth.
Treatment of LLC- OVA tumor- bearing mice with 
Nb- Fc1B (treatment schedule, online supplemental figure 
S9A) resulted in the complete depletion of CCR8+ Tregs 
in the TME (figure 6G), whereas CD4+Foxp3− T cells 
remained unaffected (figure 6H). Importantly, Tregs in 
other organs, including the tumor- draining lymph node 
and spleen, remained unaffected (figure 6I), demon-
strating the specificity of the treatment for ti- Tregs. Of 
note, a co- depletion of NK cells, but not macrophages 
or neutrophils (online supplemental figure S10A–C), 
prevented Nb- Fc1B- mediated Treg depletion (figure 6J), 
identifying NK cells as mediators of ADCC- dependent 
ti- Treg elimination.
The successful CCR8+ ti- Treg depletion resulted in 
a slightly reduced LLC- OVA tumor growth in compar-
ison to isotype- treated mice (figure 6K,L). Of note, the 
minor antitumor effect of Nb- Fc1B was comparable to 
the effect of a monotherapy with anti- PD-1 in this model 
(figure 6K,L). Since both therapies aim to increase the 
antitumor T- cell response from different angles, we 
reasoned that their combination could have a beneficial 
effect. Interestingly, the combination of both therapies 
synergistically reduced tumor growth and significantly (p 
value=0.0171) prolonged survival (figure 6K–M), accom-
panied by a strong immune influx and increased levels 
of CD8+ T cells (figure 6N,O). Moreover, this CD8+ T- cell 
population consisted mostly of highly activated CD44hi 
CD62Llo effector cells (figure 6P). Importantly, no such 
synergism was observed in CCR8- KO mice (online supple-
mental figure S11A,B), demonstrating that the observed 
antitumor effects of Nb- Fc1B are indeed CCR8- specific.
Immune- related adverse events, such as colitis, can be 
a consequence of anti- PD-1 therapy.50 To assess for such 
events, anti- PD-1 and/or Nb- Fc1B treated mice were 
subjected to a thorough evaluation of gut inflammation 
by histological examination. No histological signs of gut 
inflammation were observed in colon and ileum sections 
of any of the treatment groups (online supplemental 
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Figure 6 Specific depletion of CCR8+ ti- Tregs, but not CCR8 blockade, results in reduced LLC- OVA tumor growth and 
synergizes with anti- PD-1 therapy. (A) Schematic overview of tetravalent Nb- Fc generation. (B) Delta- MFI of CCR8 expression 
on ti- Tregs of isotype (black) or anti- CCR8 (block) (red) treated mice (n=5). (C) LLC- OVA tumor growth in isotype (black) or 
anti- CCR8 (block)- treated mice (red) (n=12). (D) Percentage of CD45+ hematopoietic cells within the TME of D16 LLC- OVA 
tumors of isotype (black) or anti- CCR8 (block)- treated mice (red) (n=5). (E) Percentage of CD4+Foxp3+ Tregs within the CD45+ 
compartment of D16 LLC- OVA tumors of isotype (black) or anti- CCR8 (block)- treated mice (red) (n=5). (F) Activation marker 
expression determined via flow cytometry, on ti- Tregs of D16 LLC- OVA tumors of isotype (black) or anti- CCR8 (block)- treated 
mice (red) (n=5). (G) Percentage of CD4+Foxp3+ Tregs within the CD45+ compartment of D16 LLC- OVA tumors of isotype (black) 
or anti- CCR8 (ADCC)- treated mice (green) (n=5). (H) Percentage of CD4+Foxp3− T cells within the CD45+ compartment of D16 
LLC- OVA tumors of isotype (black) or anti- CCR8 (ADCC)- treated mice (green) (n=5). (I) Percentage of CD4+Foxp3+ Tregs within 
the CD45+ compartment of distinct organs of isotype (black) or anti- CCR8 (ADCC)- treated (green) LLC- OVA tumor- bearing mice 
(n=5). (J) Percentage of CD4+Foxp3+ Tregs within the CD4+ compartment of D12 LLC- OVA tumors treated with isotype control 
or anti- CCR8 (ADCC) in combination with anti- NK1.1, anti- Ly6G (+ anti- rat) and/or PLX5622 (n=4). (K) s.c. LLC- OVA tumor 
growth in mice treated with isotype (black, closed circle), anti- PD-1 (black, open circle), anti- CCR8 (ADCC) (green, closed circle) 
or the combination of anti- PD-1 and anti- CCR8 (ADCC) (green, open circle) (n=12). (L) Growth of individual subcutaneous LLC- 
OVA tumors in mice treated with isotype (black, closed circle), anti- PD-1 (black, open circle), anti- CCR8 (ADCC) (green, closed 
circle) or the combination of anti- PD-1 and anti- CCR8 (ADCC) (green, open circle) (n=7). (M) Survival (tumor volume <1500 mm3) 
of LLC- OVA tumor- bearing mice treated with isotype (black, solid line), anti- PD-1 (black, dotted line), anti- CCR8 (ADCC) 
(green, solid line) or the combination of anti- PD-1 and anti- CCR8 (ADCC) (green, dotted line) (n=7). (N) Percentage of CD45+ 
hematopoietic cells within the TME of LLC- OVA tumors grown in mice treated with isotype, anti- PD-1, anti- CCR8 (ADCC) 
or the combination of anti- PD-1 and anti- CCR8 (ADCC) (n=5). (O) Percentage of distinct lymphocyte populations within the 
CD45+ compartment of LLC- OVA tumors grown in mice treated with isotype, anti- PD-1, anti- CCR8 (ADCC) or the combination 
of anti- PD-1 and anti- CCR8 (ADCC) (n=5). (P) Representative FACS plot showing the expression level of CD44 and CD62L on 
the CD8+ T cells within the TME of mice treated with a combination of anti- PD-1 and anti- CCR8 (ADCC) (n=5). (B to K, N to P) 
Data shown as mean±SEM. (B, D to J) *p<0.05, **p<0.01 and ****p<0.0001 by unpaired Student’s t- test, (C. K) **p<0.01 by two- 
way ANOVA with Holm- Sidak multiple comparisons test, (N, O) *p<0.05, **p<0.01 and ***p<0.001 by one- way ANOVA. ADCC, 
antibody- dependent cell- mediated cytotoxicity; anti- PD-1, anti- programmed cell death protein-1; ANOVA, analysis of variance; 
LLC, Lewis Lung Carcinoma; MFI, median fluorescence intensity; NK, natural killer; s.c., subcutaneously; ti- Treg, tumor- 
infiltrating regulatory T cell.
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figure S9B), with no epithelial erosion, cell death, villus 
blunting, goblet cell loss nor elevated immune infiltration 
in any of the mice. Moreover, intestinal epithelial barrier 
permeability, as measured by lumen- to- blood passage of 
orally delivered 20 kDa FITC- dextran, did not increase 
after therapy (online supplemental figure S9C), nor 
did the mice show any weight loss (online supplemental 
figure S9D). Hence, while treatment with a combina-
tion of anti- PD-1 and anti- CCR8 (Nb- Fc1B) significantly 
affects tumor growth (figure 6K–M), it does not induce 
gut inflammation.
Strikingly, the antitumoral effects observed in the 
LLC- OVA model were even further enhanced in the 
MC38 model, where Nb- Fc1B monotherapy resulted in 
complete tumor rejection in 2 out of 10 mice and the 
combination of Nb- Fc1B and anti- PD-1 therapy resulted 
in complete tumor rejection in all mice after therapy 
ceased (figure 7A–C). Moreover, re- challenge of the 
Figure 7 Specific depletion of CCR8+ ti- Tregs reduces MC38 tumor growth as monotherapy and synergizes with anti- PD-1 
therapy. (A) s.c. MC38 tumor growth in mice treated with isotype (black, closed circle), anti- PD-1 (black, open circle), anti- 
CCR8 (ADCC) (green, closed circle) or the combination of anti- PD-1 and anti- CCR8 (ADCC) (green, open circle) (n=10). (B) 
Tumor growth of individual subcutaneous MC38 tumors grown in mice treated with isotype (black, closed circle), anti- PD-1 
(black, open circle), anti- CCR8 (ADCC) (green, closed circle) or the combination of anti- PD-1 and anti- CCR8 (ADCC) (green, 
open circle) (n=10). (C) Survival (tumor volume <1500 mm3) of MC38 tumor- bearing mice treated with isotype (black, solid line), 
anti- PD-1 (black, dotted line), anti- CCR8 (ADCC) (green, solid line) or the combination of anti- PD-1 and anti- CCR8 (ADCC) 
(green, dotted line) (n=10). (D) Individual tumor volumes in mice subcutaneously re- challenged with MC38 after complete tumor 
regression on treatment with anti- CCR8 (ADCC) (green, closed circle) (n=2) or the combination of anti- PD-1 and anti- CCR8 
(ADCC) (green, open circle) (n=8). (A) Data shown as mean±SEM. (A) **p<0.01 by two- way ANOVA with Holm- Sidak multiple 
comparisons test. ADCC, antibody- dependent cell- mediated cytotoxicity; anti- PD-1, anti- programmed cell death protein-1; 
ANOVA, analysis of variance; s.c., subcutaneously.
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complete responders with MC38 resulted in full tumor 
rejection in 2 out of 2 monotherapy and 7 out of 8 combi-
nation therapy- treated mice, indicative of a strong immu-
nological memory (figure 7D). These results demonstrate 
that CCR8- targeted depletion of ti- Tregs unleashes anti-
tumor immunity and synergizes with immune checkpoint 
blockade.
DISCUSSION
Recent studies in distinct human cancer types (breast, 
lung, colon and liver) have shown the unique upregu-
lation of CCR8 expression by ti- Tregs.18–21 Employing 
mouse tumor models, we demonstrated that Ccr8 gene 
expression in the TME is indeed restricted to TCRβ+ 
cells. However, subsequent single- cell RNA sequencing of 
the LLC- OVA tumor- infiltrating TCRβ+ cell compartment 
revealed that Ccr8 expression was not restricted to ti- Tregs, 
but could also be found in populations of dysfunctional 
CD4+ and CD8+ T cells. Hence, Ccr8 is part of a common 
gene signature between Foxp3+ Tregs and Foxp3− dysfunc-
tional T cells, also including Pdcd1, Lag3 and Havcr2. 
Remarkably, the CCR8 protein is differentially expressed 
by the Ccr8- positive cell types, with a high expression on 
ti- Tregs, a lower expression on dysfunctional CD4+ T cells 
and no detectable protein expression on dysfunctional 
CD8+ T cells. This appears to be an intrinsic difference 
between these T- cell types, since the polyclonal stimula-
tion of C57BL/6 splenocytes or lymph node cells strongly 
induces CCR8 expression on Tregs and to a lesser extent 
on Foxp3−CD4+ T cells, but not on CD8+ T cells. Hence, 
high CCR8 expression is especially prominent on TCR- 
triggered, antigen- experienced Tregs. We demonstrated 
that the induction of CCR8 surface expression is at least 
partly dependent on NF-κB, which may initiate Ccr8 
gene expression by occupying Ccr8 regulatory elements 
but may also have post- transcriptional effects. Alvisi et al 
hypothesized that Ccr8 is part of a core network of immu-
nosuppressive genes that is regulated by the transcrip-
tion factor IRF4 in collaboration with BATF.51 These data 
could be reconciled by the finding that NF-κB and IRF4 
may co- regulate the expression of genes associated with 
T- cell functions,52 possibly including Ccr8.
A more detailed analysis of the ti- Treg compartment at 
the single cell level revealed two distinct ti- Treg subsets, 
one of which showed a unique upregulation of Ccr8 gene 
expression, co- expression of several activation markers 
and immune checkpoint molecules, and a superior 
suppressive activity. Similarly, protein expression of CCR8 
in human NSCLC and melanoma tumors was restricted to 
the activated (OX-40+) CD3+CD4+CD127−CD25+ ti- Tregs. 
These findings are in line with the recent study on NSCLC 
patients where CCR8+ICOS+ ti- Tregs were identified as 
effector Tregs with a superior suppressive capacity.51
However, it remained unclear how specific CCR8 expres-
sion is for ti- Tregs, which is crucial information for the 
therapeutic applicability of CCR8- targeted approaches. 
In naive and tumor- bearing mice, CCR8 expression could 
be detected on a fraction of thymic Tregs. However, this 
thymic CCR8 expression was previously shown to be redun-
dant for thymocyte development, with CCR8- KO mice 
showing normal thymocyte differentiation, motility and 
negative selection.53 Hence, CCR8- targeting is unlikely to 
interfere with normal T- cell development. Interestingly, 
in tumor- bearing mice, upregulation of CCR8 expression 
on Tregs could already be detected in the tumor- draining 
lymph node and spleen, but not in any other tissue except 
the thymus. These data may indicate Treg activation in 
the lymphoid organs prior to homing to the TME, as has 
been previously suggested.54 However, despite previous 
reports on a potential role for CCR8 in the recruitment,54 
activation and/or suppressive capacity55 of Tregs, we 
observed that a lack of CCR8 expression or a Nb- me-
diated blockade of CCR8 signaling did not affect these 
Treg characteristics, nor did it affect tumor growth. This 
finding is in apparent contrast to Villarreal et al, where 
anti- CCR8 mAb therapy was reported to inhibit CCR8 
signaling, resulting in slower tumor growth and improved 
survival in a mouse model of colon cancer.56 Since treat-
ment with the mAb also resulted in a decreased frequency 
of CCR8+ ti- Tregs, it is likely that this anti- CCR8 mAb also 
resulted in Fc- mediated cell depletion.56
To solve the issue whether CCR8 blockade would be 
sufficient or whether the depletion of CCR8+ cells is 
required to enhance antitumor immunity, we generated 
strong CCR8- blocking tetravalent Nb- based moieties that 
only differ at their ADCC effector function, either ADCC- 
prone (afucosylated Fc) or ADCC- deficient (LALAPG 
mutated Fc). These unique novel tools clearly showed 
that (1) CCR8 blockade without ADCC is not sufficient 
for therapeutic efficacy and that (2) anti- CCR8 (ADCC- 
prone) Nb treatment resulted in the complete NK- me-
diated depletion of CCR8+ Tregs in the TME, without 
affecting Foxp3−CD4+ T cells or any Tregs in the periphery, 
strongly increasing the safety profile of this compound. 
This contrasts the treatment with the FDA (Food and Drug 
Administration)- approved CD25- blocking mAb dacli-
zumab, which has been shown to mediate a prolonged 
depletion of CD4+CD25+ Tregs from the circulation9 and 
the anti- mouse CD25 mAb (PC61) depleting CD4+CD25+ 
Tregs from peripheral lymphoid tissues.12
Our data show an antitumor effect of the anti- CCR8 
(ADCC- prone) monotherapy, but especially a synergistic 
action with anti- PD-1. It has been shown that anti- PD-1 
treatment may lead to the expansion of ti- Tregs and hyper-
progression of the tumors,57 58 a phenomenon which 
would be counteracted by the concomitant depletion of 
ti- Tregs. The reduction in tumor growth of the combina-
tion therapy could be attributed to a more immunogenic 
TME rich in effector CD8+ T cells. This altered balance 
between suppressive ti- Tregs and effector CD8+ T cells 
has been reported to be crucial for an effective antitumor 
immune response.5 59
It has previously been shown that a fraction of 
patients treated with anti- PD-1 are prone to develop 
immune- related adverse events (irAEs) such as colitis 
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and particularly when anti- PD-1 is combined with other 
immune checkpoint inhibitors such as anti- CTLA-4.50 
However, no signs of irAEs including gut inflammation 
were observed in any of our treatment groups.
Together our study compiles strong evidence to suggest 
that a specific depletion of ti- Tregs, using the ti- Treg 
specific marker CCR8 as molecular target, could be used 
as a powerful additive in current immunotherapies. The 
finding that CCR8 upregulation can be detected on 
effector ti- Tregs of multiple human cancer types by both 
this study and previous studies18–23 supports a broad appli-
cability of CCR8+ cell- depleting therapeutics in the clinic.
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